Xbrane Biopharma AB
Research Xbrane Biopharma AB (XBRANE) on Bullrun: market cap SEK 195.75M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXBRANE
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 195.75M
- Financial periodQ2 2026
- RevenueSEK 46.75M
- Net income-SEK 11.42M
- Free cash flow-SEK 17.38M
- Gross margin5.1%
Valuation Snapshot
latest market cap is SEK 195.75M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | SEK 195.75M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xbrane Biopharma AB's market cap?
Xbrane Biopharma AB's market capitalization is SEK 195.75M.
What does Xbrane Biopharma AB do?
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.